Immunicum AB: Invitation to Investor Events Pres
Post# of 301275
Press release
November 22, 2017
Invitation to Investor Events
Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that CEO Carlos de Sousa will present the Company as well as provide background on the previously announced proposed Rights Issue at two upcoming investor events.
Aktiespararna Stora Aktiedagen in Gothenburg Date: Monday, November 27, 2017 Presentation Time: 10:10-10:40 CET Location: Svenska Mässan, Mässans Gata 8, Gothenburg Please register to attend at https://www.aktiespararna.se/aktiviteter/stor...n-goteborg .
Immunicum Investor Event in Stockholm Date: Thursday, November 30, 2017 Presentation Time : 18:00-19:00 CET Location: United Spaces, Waterfront Building, Floor 2, Klarabergsviadukten 63, Stockholm After the presentation, there is an opportunity to enjoy drinks and refreshments. Please register to attend by emailing info@immunicum.com no later than Tuesday, November 28, 2017.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com
Investor relations, sweden
Helena Stångberg Hallvarsson & Halvarsson Telephone: + 46 709 71 12 53 E-mail: ir@immunicum.com
Investor and Media Relations EU/US
Gretchen Schweitzer Trophic Communications Telephone: +49 172 861 8540 E-mail: ir@immunicum.com
The Company's Certified Adviser is Redeye AB Telephone: +46 (0) 8 545 013 31 www.redeye.se
| about IMMUNICUM AB (PUBL) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq First North Premier. www.immunicum.com |
(0)
(0)